The safety of ustekinumab for the treatment of psoriatic arthritis.

about

The safety of ustekinumab for the treatment of psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38820480

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The safety of ustekinumab for the treatment of psoriatic arthritis.

@en

type

Item

label

The safety of ustekinumab for the treatment of psoriatic arthritis.

@en

prefLabel

The safety of ustekinumab for the treatment of psoriatic arthritis.

@en

P1476

The safety of ustekinumab for the treatment of psoriatic arthritis.

@en

P2093

A Laiz

http://www.w3.org/2001/XMLSchema#string

A López-Ferrer

http://www.w3.org/2001/XMLSchema#string

P2860

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

P304

733-742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1323864

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luis Puig

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28441904

http://www.w3.org/2001/XMLSchema#string

The safety of ustekinumab for the treatment of psoriatic arthritis.

about

The safety of ustekinumab for the treatment of psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698